Recent Finacing
Recent Raise
Profectus BioSciences develops vaccines and antibody therapeutics for chronic and emerging viral diseases—including an m102.4 post-exposure antibody for Nipah/Hendra—collaborating on preclinical programs and cGMP mammalian cell production.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor